Core Insights - The collaboration between East China Pharmaceutical and Hangzhou Changxi Pharmaceutical focuses on the exclusive commercialization of the inhalation drug CXG87 in mainland China, marking a significant step in the high-barrier inhalation formulation sector [1][2] - CXG87 is a modified inhalation powder combining budesonide and formoterol, aimed at treating asthma and other respiratory diseases, with its Phase III clinical trials completed and a new drug application expected in the first half of 2026 [2][3] - The inhalation formulation market in China is projected to reach approximately 23.9 billion yuan by 2025, with a potential market space of up to 60 billion yuan due to unmet medical needs among respiratory disease patients [3] Company Overview - East China Pharmaceutical will leverage its extensive market resources to lead the commercialization of CXG87, supported by a professional marketing team and a multi-channel sales network across over 30 provinces in China [4][6] - The company has demonstrated strong commercial capabilities, with its innovative product segment achieving a revenue of 1.084 billion yuan in the first half of 2025, reflecting a significant year-on-year growth of 59% [4][5] - East China Pharmaceutical has successfully commercialized several innovative products, including CAR-T therapies and monoclonal antibodies, establishing a solid foundation for managing complex inhalation products like CXG87 [5][6]

10月9日，华东医药（000963）股份有限公司(000963.SZ，简称"华东医药")正式宣布，与杭州畅溪制药 有限公司(简称"畅溪制药")就其改良型呼吸系统药物CXG87(改良型布地奈德/福莫特罗吸入粉雾剂)达成 在中国大陆地区的独家商业化合作。 根据协议，畅溪制药作为药品上市许可持有人，将全面负责CXG87的研发、注册、生产和供应链管 理；华东医药则将凭借其深厚的市场资源，主导该产品在中国大陆的商业化推广。此次合作通过首付 款、注册里程碑及销售里程碑等付款方式，实现了双方利益的深度绑定。 这一合作标志着国内药企在技术壁垒极高的吸入制剂领域迈出了关键一步，旨在将一款更具临床优势的 创新疗法引入市场，以满足广大呼吸系统疾病患者尚未被满足的医疗需求。 CXG87突破技术壁垒，助推国产吸入新药惠及气流受限患者 本次合作的核心产品CXG87，其本质是一种吸入用布地奈德/福莫特罗干粉吸入剂，是畅溪制药自主开 发的2.2类新药，用于治疗哮喘等呼吸系统疾病。目前，该药物针对哮喘适应症的III期临床试验已完成 全部受试者入组，预计将于2026年上半年递交新药上市申请。 CXG87产品的创新之处在于实现了制剂与给药装置的双 ...